Herpes Simplex Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's, "Herpes Simplex Pipeline Insights 2026" Report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Herpes Simplex pipeline landscape. It covers the Herpes Simplex pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Herpes Simplex pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Herpes Simplex Pipeline @ Herpes Simplex Pipeline Outlook- https://www.delveinsight.com/sample-request/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Herpes Simplex Pipeline Report
• In March 2026, MAXVAX Biotechnology Limited Liability Company conducted a phase III study to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
• In January 2026, Shanghai Institute Of Biological Products initiated a clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase II).
• DelveInsight's Herpes Simplex pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Herpes Simplex treatment.
• The leading Herpes Simplex Companies such as RedBioTec, TGV-Laboratories, Maruho, AiCuris, Sanofi, Glaxosmithkline, Starpharma, ReceptoPharm and others.
• Promising Herpes Simplex Pipeline Therapies such as famciclovir, ASP2151, GSK208141, 2LHERP®, walnut extract, Pritelivir, BTL-TML-HSV, HerpV and QS-21 and others.

Stay ahead with the most recent pipeline outlook for Herpes Simplex @ Herpes Simplex Treatment Drugs- https://www.delveinsight.com/sample-request/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Herpes Simplex Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Herpes Simplex Pipeline Report also highlights the unmet needs with respect to the Herpes Simplex.

Herpes Simplex Overview
Infection with herpes simplex virus, commonly known as herpes, can be due to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). HSV-1 is mainly transmitted by oral-to-oral contact to cause infection in or around the mouth (oral herpes). However, HSV-1 can also be transmitted through oral-genital contact to cause infection in or around the genital area ( genital herpes). HSV-2 is almost exclusively transmitted through genital-to-genital contact during sex, causing infection in the genital or anal area (genital herpes). Symptoms of oral herpes include painful blisters or open sores called ulcers in or around the mouth. Sores on the lips are commonly referred to as "cold sores." Genital herpes caused by HSV-1 can be asymptomatic or can have mild symptoms that go unrecognized. When symptoms do occur, genital herpes is characterised by 1 one or more genital or anal blisters or ulcers. Antiviral medications, such as acyclovir, famciclovir, and valacyclovir, are the most effective medications available for people infected with HSV. These can help to reduce the severity and frequency of symptoms, but cannot cure the infection.

Herpes Simplex Emerging Drugs Profile
• Pritelivir: AiCuris
Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients. It has received the US FDA Breakthrough Therapy Designation. AiCuris Anti-infective Cures AG has begun Phase III development of its lead compound pritelivir, a novel helicase-primase inhibitor, for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

• UB-621: United BioPharma
UB-621 is a first-in-class anti-gD mAb (UB-621) with demonstrated strong viral suppression of transmission and recurrence of HSV1 and HSV2, developed over ten years of research collaboration between the University of Washington, the National Institute for Allergy and Infectious Diseases, University of Duisburg Essen, Germany, and Dartmouth College. In October 2021 United BioPharma announced that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic. Together with United BioPharma, the two institutions will test the effectiveness of UB-621, a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2) in preparation for phase II trials in the United States and China.

The Herpes Simplex Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Simplex with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Simplex Treatment.
• Herpes Simplex Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Herpes Simplex Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Simplex market

Explore groundbreaking therapies and clinical trials in the Herpes Simplex Pipeline @ New Herpes Simplex Drugs- https://www.delveinsight.com/sample-request/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Simplex Companies
RedBioTec, TGV-Laboratories, Maruho, AiCuris, Sanofi, Glaxosmithkline, Starpharma, ReceptoPharm and others.

Herpes Simplex Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Herpes Simplex Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn about new drugs, pipeline developments with DelveInsight's expert analysis @ Herpes Simplex Market Drivers and Barriers- https://www.delveinsight.com/sample-request/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Herpes Simplex Pipeline Report
• Coverage- Global
• Herpes Simplex Companies-RedBioTec, TGV-Laboratories, Maruho, AiCuris, Sanofi, Glaxosmithkline, Starpharma, ReceptoPharm and others.
• Herpes Simplex Pipeline Therapies- famciclovir, ASP2151, GSK208141, 2LHERP®, walnut extract, Pritelivir, BTL-TML-HSV, HerpV and QS-21 and others
• Herpes Simplex Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Herpes Simplex Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Herpes Simplex Therapies and clinical trials @ Herpes Simplex Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Herpes Simplex: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Herpes Simplex- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pritelivir: AiCuris
9. Drug name: Company name
10. Drug profiles in the detailed report.....
11. Mid Stage Products (Phase II)
12. UB-621: United BioPharma
13. Drug profiles in the detailed report.....
14. Early Stage Products (Phase I)
15. SP0148: Sanofi
16. Drug name: Company name
17. Drug profiles in the detailed report.....
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report.....
21. Inactive Products
22. Herpes Simplex Key Companies
23. Herpes Simplex Key Products
24. Herpes Simplex- Unmet Needs
25. Herpes Simplex- Market Drivers and Barriers
26. Herpes Simplex- Future Perspectives and Conclusion
27. Herpes Simplex Analyst Views
28. Herpes Simplex Key Companies
29. Appendix

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.